J Cancer 2021; 12(20):6216-6230. doi:10.7150/jca.62402 This issue

Review

The regulatory networks of the Hippo signaling pathway in cancer development

Maonan Wang1,2, Manli Dai3, Dan Wang1,2, Wei Xiong1,2, Zhaoyang Zeng1,2✉, Can Guo1,2✉

1. NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
2. Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China.
3. Hunan Food and Drug Vocational College, Changsha 410036, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Wang M, Dai M, Wang D, Xiong W, Zeng Z, Guo C. The regulatory networks of the Hippo signaling pathway in cancer development. J Cancer 2021; 12(20):6216-6230. doi:10.7150/jca.62402. Available from https://www.jcancer.org/v12p6216.htm

File import instruction

Abstract

Graphic abstract

The Hippo signaling pathway is a relatively young tumor-related signaling pathway. Although it was discovered lately, research on it developed rapidly. The Hippo signaling pathway is closely relevant to the occurrence and development of tumors and the maintenance of organ size and other biological processes. This manuscript focuses on YAP, the core molecule of the Hippo signaling pathway, and discussion the upstream and downstream regulatory networks of the Hippo signaling pathway during tumorigenesis and development. It also summarizes the relevant drugs involved in this signaling pathway, which may be helpful to the development of targeted drugs for cancer therapy.

Keywords: Hippo signaling pathway, YAP, Tumor development